Efficacy and safety of sorafenib in patients with advanced clear-cell renal-cell carcinoma (RCC) with bone metastases: results from the phase III TARGET study

被引：0
|
作者：
Gschwend, J. E. [1 ]
Bukowski, R. [2 ]
Eisen, T. [3 ]
Stadler, W. S. [4 ]
Szczylik, C. S. [5 ]
Oudard, O. S. [6 ]
Siebels, M. S. [7 ]
Michel, M. S. [8 ]
Grimm, M. O. [9 ]
Escudier, B. E. [10 ]
机构：
[1] Tech Univ Munich, Klinikum Rechts Isar, Urol Klin & Poliklin, Munich, Germany
[2] Cleveland Clin Taussig Canc Ctr, Cleveland, OH USA
[3] Cambridge Res Inst, Cambridge, England
[4] Univ Chicago, Chicago, IL 60637 USA
[5] Mil Med Acad, Warsaw, Poland
[6] Hop Euopeen Georges Pompidou, Paris, France
[7] LMU, Klinikum Grosshadern, Munich, Germany
[8] Univ Klinikum Mannheim, Mannheim, Germany
[9] Klinikum Carl Gustav Carus, Dresden, Germany
[10] Inst Gustave Roussy, Villejuif, France
来源：
ONKOLOGIE | 2010年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：130 / 131
页数：2
相关论文
共 50 条
  • [31] Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET
    S. Negrier
    E. Jäger
    C. Porta
    D. McDermott
    M. Moore
    J. Bellmunt
    S. Anderson
    F. Cihon
    J. Lewis
    B. Escudier
    R. Bukowski
    Medical Oncology, 2010, 27 : 899 - 906
  • [32] STEROID-RECEPTORS IN THE METASTASES FROM HUMAN RENAL-CELL CARCINOMA (RCC)
    CONCOLINO, G
    MAROCCHI, A
    TENAGLIA, R
    DISILVERIO, F
    PROSTATE, 1983, 4 (06): : 663 - 663
  • [33] Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival.
    Eisen, T.
    Bukowski, R. M.
    Staehler, M.
    Szczylik, C.
    Oudard, S.
    Stadler, W. M.
    Schwartz, B.
    Simantov, R.
    Shan, M.
    Escudier, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 223S - 223S
  • [34] Predictive and prognostic factors in a phase III study of pazopanib in patients with advanced renal cell carcinoma (RCC)
    Sternberg, C.
    Davis, I.
    Wagstaff, J.
    Hawkins, R.
    Chen, M.
    Ding, J.
    EJC SUPPLEMENTS, 2009, 7 (02): : 424 - 424
  • [35] EMBOLIZATION OF PELVIC BONE METASTASES FROM RENAL-CELL CARCINOMA
    BRAEDEL, HU
    ZWERGEL, U
    KNOPP, W
    EUROPEAN UROLOGY, 1984, 10 (06) : 380 - 384
  • [36] A phase III randomized study with sorafenib in patients with advanced renal cell cancer
    Procopio, G.
    Verzoni, E.
    Porta, C.
    Escudier, B.
    Martinetti, A.
    Catena, L.
    DeDosso, S.
    Bajetta, R.
    Gevorgyan, A.
    Bajetta, E.
    ANNALS OF ONCOLOGY, 2006, 17 : XI3 - XI3
  • [37] A randomized, open label, multicenter phase 2 study to evaluate the efficacy of sorafenib in patients (pts) with advanced Renal Cell Carcinoma (RCC) after a radical resection of the metastases.
    Verzoni, Elena
    Grassi, Paolo
    Montone, Rosanna
    Maggi, Claudia
    Cognetti, Francesco
    Milella, Michele
    Bearz, Alessandra
    Ortega, Cinzia
    Morelli, Franco
    Chiuri, Vincenzo Emanuele
    Necchi, Andrea
    De Braud, Filippo G.
    Procopio, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [38] A phase III randomized study with sorafenib in patients with advanced Renal Cell Cancer
    Procopio, G.
    Verzoni, E.
    Porta, C.
    Escudier, B.
    Martinetti, A.
    Catena, L.
    DeDosso, S.
    Bajetta, R.
    Gevorgyan, A.
    Bajetta, E.
    ANNALS OF ONCOLOGY, 2006, 17 : XI3 - XI3
  • [39] Plasma biomarkers predicting outcome in patients with advanced RCC: Results from the sorafenib phase III TARGET trial
    Pena, Carol
    Shan, Michael
    Bukowski, Ronald M.
    Escudier, Bernard
    Lathia, Chetan
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [40] Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study
    Procopio, Giuseppe
    Apollonio, Giulia
    Cognetti, Francesco
    Miceli, Rosalba
    Milella, Michele
    Mosca, Alessandra
    Chiuri, Vincenzo Emanuele
    Bearz, Alessandra
    Morelli, Franco
    Ortega, Cinzia
    Atzori, Francesco
    Donini, Maddalena
    Ratta, Raffaele
    Raimondi, Alessandra
    Claps, Melanie
    Martinetti, Antonia
    Capitanio, Umberto
    de Braud, Filippo G.
    Cappelletti, Vera
    Verzoni, Elena
    EUROPEAN UROLOGY ONCOLOGY, 2019, 2 (06): : 699 - 707
12345